L. SHAPIRO

Application No.: 09/518,081

## EXHIBIT B

## MARKED-UP VERSION OF THE CLAIMS U.S. PATENT APPLICATION NO. 09/518,081

1. (Twice Amended) A method of inhibiting apoptosis in a subject, comprising: administering a therapeutically effective amount of at least one serine protease inhibitor in which the effective amount inhibits apoptosis;

wherein the subject suffers from at least one of wasting disease, neurodegenerative disease, myocardial infarction, stroke, Alzheimer's disease, arthritis, muscular dystrophy, Downs Syndrome, sepsis, HIV infection, multiple sclerosis, arteriosclerosis, diabetes[, arthritis], autoimmune disease, ischemia-reperfusion injury, or toxin-induced liver injury.

- 3. (Amended) The method of Claim 1, in which the serine protease inhibitor is  $\alpha_1$ -antitrypsin, [an  $\alpha_1$ -antitrypsin-like agent, a variant of  $\alpha_1$ -antitrypsin, an anticathepsin G agent, an antitryptase TL-2 agent, an antifactor Xa agent, an antielastase agent, an antiproteinase-3 agent, an oxidation-resistant or free radical-resistant variant thereof, or combinations thereof.
- 4. (Twice Amended) The method of Claim 3 in which the effective amount is [greater than 0.2]at least .001 and [less than 8.0]no greater than 70 g/kg body weight.
- 8. (Twice Amended) The method of Claim 1, in which the serine protease inhibitor is selected from the group consisting of:

- i. (benzyloxycarbonyl)-L-valyl-N-[1-(3-(5-(3-trifluoromethylbenzyl)-1,2,4-oxadiazolyl)carbonyl)-2-(S)-methylpropyl]-L-prolinamide;
- ii. (benzyloxycarbonyl)-L-valyl-N-[1-(3-(5-(2-phenylethyl)-1,2,4-oxadiazolyl)carbonyl)-2-(S)-methylpropyl]-L-prolinamide;
- iii. (benzyloxycarbonyl)-L-valyl-N-[1-(3-(5-(2-methoxybenzyl)-1,2,4-oxadiazolyl)carbonyl)-2-(S)-methylpropyl]-L-prolinamide;
- iv. (benzyloxycarbonyl)-L-valyl-N-[1-(3-(5-(trifluoromethyl)-1,2,4-oxadiazolyl)carbonyl)-2-(S)-methylpropyl]-L-prolinamide;
- v. (benzyloxycarbonyl)-L-valyl-N-[1-(3-(5-(methyl)-1,2,4-oxadiazolyl)carbonyl)-2-(S)-[M]methylpropyl]-L-[P]prolinamide;
- vi. ([B]<u>b</u>enzyloxycarbonyl)-L-[V]<u>v</u>alyl-N-[1-(3-(5-(difluoromethyl)-1,2,4-oxadiazolyl)[]carbonyl)-2-(S)-[M]<u>m</u>ethylpropyl]-L-[P]<u>p</u>rolinamide;
- vii. ([B]<u>b</u>enzyloxycarbonyl)-L-[V]<u>v</u>alyl-N-[1-(3-(5-(benzyl)-1,2,4-oxadiazolyl)carbonyl)-2-(S)-[M]<u>m</u>ethylpropyl]-L-[P]<u>p</u>rolinamide;
- viii. ([B]<u>b</u>enzyloxycarbonyl)-L-[V]<u>v</u>alyl-N-[1-(3-(5-(3-methoxybenzyl)-1,2,4-oxadiazolyl)carbonyl)-2-(S)-[M]<u>m</u>ethylpropyl]-L-[P]<u>p</u>rolinamide;
- ix.  $([B]\underline{b}enzyloxycarbonyl)-L-[V]\underline{v}alyl-N-[1-(3-(5-(2,6-difluorobenzyl)-1,2,4-oxadiazolyl)carbonyl)-2-(S)-[M]\underline{m}ethylpropyl]-L-[P]\underline{p}rolinamide;$
- x. ([B] $\underline{b}$ enzyloxycarbonyl)-L-[V] $\underline{v}$ alyl-N-[1-(3-(5-(trans-styryl)-1,2,4-oxadiazolyl)carbonyl)-2-(S)-[M] $\underline{m}$ ethylpropyl]-L-[P] $\underline{p}$ rolinamide;
- xi. ([B]<u>b</u>enzyloxycarbonyl)-L-[V]<u>v</u>alyl-N-[1-(3-(5-(trans-4-[T]<u>t</u>rifluoro methylstyryl)-1,2,4-oxadiazolyl)carbonyl)-2-(S)-[M]<u>methylpropyl</u>]-L-[P]<u>prolinamide</u>;

- xii. ([B]<u>b</u>enzyloxycarbonyl)-L-[V]<u>v</u>alyl-N-[1-(3-(5-(trans-4-[M]<u>m</u>ethoxystyryl)-1,2,4-oxadiazolyl)carbonyl)-2-(S)-[M]<u>m</u>ethylpropyl]-L-[P]<u>p</u>rolinamide;
- xiii. ([B]<u>b</u>enzyloxycarbonyl)-L-[V]<u>v</u>alyl-N-[1-(3-(5-(3-[T]<u>t</u>hienylmethyl)-1,2,4-oxadiazolyl)carbonyl)-2-(S)-[M]<u>m</u>ethylpropyl]-L-[P]<u>p</u>rolinamide;
- xiv. ([B]<u>b</u>enzyloxycarbonyl)-L-[V]<u>v</u>alyl-N-[1-(3-(5-([P]<u>p</u>henyl)-1,2,4-oxadiazolyl)carbonyl[])-2-(S)-methylpropyl]-L-prolinamide;
- xv. ([B]<u>b</u>enzyloxycarbonyl)-L-[V]<u>v</u>alyl-N-[1-(3-(5-(3-[P]<u>p</u>henylpropyl)-1,2,4-oxadiazolyl)carbonyl)-2-(S)-[M]<u>m</u>ethylpropyl]-L-[P]<u>p</u>rolinamide;
- xvi. [B](benzyloxycarbonyl)-L-valyl-N-[1-(2-[[](5-(3-methylbenzyl)-1,3,4-oxadiazolyl[]])carbonyl)-2-(S)-methylpropyl]-L-prolinamide (also known as CE-2072)[,];
- xvii. [B](benzyloxycarbonyl)-L-valyl-N-[1-(2-(3-(methylbenzyl)-1,3,4-oxadiazolyl[]])carbonyl)-2-(S)-methylpropyl]-L-prolinamide;
- xviii. [B](benzyloxycarbonyl)-L-valyl-N-[1-(2-(5-(methyl)-1,3,4-oxadiazoly[]])carbonyl)-[]2-(S)-methylpropyl]-L-prolinamide;
- xix. [B](benzyloxycarbonyl)-L-valyl-N-[1-(2-(5-(3-trifluoromethylbenzyl)-1,3,4-oxadiazolyl[]])carbonyl)-2-(S)-methylpropyl]-L-prolinamide;
- xx. ([B]benzyloxycarbonyl)-L-valyl-N-[1-(2-(5-(4-[D]dimethylamino[]benzyl)-1,3,4-oxadiazolyl[]])carbonyl)-2-(S)-methylpropyl]-L-prolinamide;
- xxi. [B]benzyloxycarbonyl)-L-valyl-N-[1-(2-(5-(1-napthylenyl)-1,3,4-oxadiazolyl[]])carbonyl)-2-(S)-methylpropyl]-L-prolinamide;
- xxii. ([B]benzyloxycarbonyl)-L-valyl-[1-(3-(5-(3,4-methylenedioxybenzyl)-1,2,4[]-oxadiazolyl[]])carbonyl)-2-(S)-methylpropyl]-L-prolinamide;

xxiii. [B](benzyloxycarbonyl)-L-valyl-N-[1-(3-(5-(3,5-dimethylbenzyl)-1,2,4-oxadiazolyl[]])carbonyl)-2-(S)-methylpropyl]-L-prolinamide;

xxiv. ([B]benzyloxycarbonyl)-L-valyl-N-[1-(3-(5-(3,5-dimethoxybenzyl)-1,2,4-oxadiazolyl[]])carbonyl)-2-(S)-methylpropyl]-L-prolinamide;

xxv. ([B]benzyloxycarbonyl)-L-valyl-N-[1-(3-(5-(3,5-ditrifluoromethylbenzyl)-1,2,4[]-oxadiazolyl[]])carbonyl)-2-(S)-methylpropyl]-L-prolinamide;

xxvi. ([B]benzyloxycarbonyl)-L-valyl-N-[1-(3-(5-(3-methylbenzyl)-1,2,4-oxadiazolyl[]])carbonyl)-2-(S)-methylpropyl]-L-prolinamide;

xxvii. ([B]benzyloxycarbonyl)-L-valyl-N-[1-(3-(5-(biphenylmethine)-1,2,4-oxadiazolyl []])carbonyl)-2-(S)-methylpropyl]-L-prolinamide;

xxviii. ([B]<u>b</u>enzyloxycarbonyl)-L-valyl-N-[1-(3-(5-(4-phenylbenzyl)-1,2,4-oxadiazolyl[]])carbonyl)-2-(S)-methylpropyl]-L-prolinamide;

xxix. ([B]benzyloxycarbonyl)-L-valyl-N-[1-(3-(5-(3-phenylbenzyl)-1,2,4-[]oxadiazolyl[]])carbonyl)-2-(S)-methylpropyl]-L-prolinamide;

xxx. ([B]benzyloxycarbonyl)-L-valyl-N-[1-(3-(5-(3-phenoxybenzyl)-1,2,4-oxadiazolyl[]])carbonyl)-2-(S)-methylpropyl]-L-prolinamide;

xxxi. ([B]benzyloxycarbonyl)-L-valyl-N-[1-(3-(5-(cyclohexylmethylene)-1,2,4-oxadiazolyl[]])carbonyl)-2-(S)-methylpropyl]-L-prolinamide;

xxxii. ([B]benzyloxycarbonyl)-L-valyl-N-[1-(3-(5-(3-

trifluoromethyldimethylmethylene[])-1,2,4-oxadiazolyl[]])carbonyl)-2-(S)-methylpropyl]-L-prolinamide;

xxxiii. ([B]benzyloxycarbonyl)-L-valyl-N-[1-(3-(5-(1-napthylmethylene)-1,2,4-oxadiazolyl[]])carbonyl)-2-(S)-methylpropyl]-L-prolinamide;

xxxiv. ([B]benzyloxycarbonyl)-L-valyl-N-[1-(3-(5-(3-pyridylmethyl)-1,2,4-oxadiazolyl[]])carbonyl)-2-(S)-methylpropyl]-L-prolinamide;

xxxv. ([B]benzyloxycarbonyl)-L-valyl-N-[1-(3-(5-(3,5-diphenylbenzyl)-1,2,4-oxadiazolyl[]])carbonyl)-2-(S)-methylpropyl]-L-prolinamide;

xxxvi. ([B]benzyloxycarbonyl)-L-valyl-N-[1-(3-(5-(4-dimethylaminobenzyl)-1,2,4-oxadiazolyl[]])carbonyl)-2-(S)-methylpropyl]-L-prolinamide;

xxxvii. 2-[(][5-[([B]benzyloxycarbonyl)amino]-6-oxo-2-(4-fluorophenyl)-1,6-dihydro-1-pyrimidinyl]-N-[1-(3-(5-(3-trifluoromethylbenzyl)-1,2,4-oxadiazolyl[]])carbonyl)-[](S)-2-methylpropyl]acetamide;

xxxviii. 2-(5-[A]amino-6-oxo-2-(4-fluorophenyl)-1,6-dihydro-1-pyrimidinyl]-N[1-(3-(5-[](3-trifluoromethylbenzyl)-1,2,4-oxadiazolyl[]])carbonyl)-2-(S)methylpropyl]acetamide;

xxxix. 2-[(][5-[([B]benzyloxycarbonyl)amino]-6-oxo-2-(4-fluorophenyl)-1,6-dihydro-1-pyrimidinyl]-N-[1-(2-(5-(3-methylbenzyl)-1,3,4-oxadiazolyl[]])carbonyl)-(S)-2-methylpropyl]acetamide;

- xl. 2-[(][5-[A]amino-6-oxo-2-(4-fluorophenyl)-1,6-dihydro-1-pyrimidinyl]-N-[1-(2-(5-[](3-methylbenzyl)-1,3,4-oxadiazolyl[]])carbonyl)-2-methylpropyl]acetamide;
- xli. ([P]pyrrole-2-carbonyl)-N-(benzyl)glycyl-N-[1-(2-(5-(3-methylbenzyl)-1,3,4-oxadiazolyl[]])carbonyl)-2-(S)-methylpropyl]amide;
- xlii. ([P]pyrrole-2-carbonyl)-N-(benzyl)glycyl-N-[1-(3-(5-(3-trifluoromethylbenzyl)[](-1,2,4-oxadiazolyl)-(S)-methylpropyl]amide;

L. SHAPIRO

Application No.: 09/518,081

xliii. (2S,5S)-5-[A]amino-1,2,4,5,6,7-hexahydroazepino-[3,2,1]-indole-4-one-carbonyl[]-N-[1-(2-(5-(3-methylbenzyl)-1,3,4-oxadiazolyl[]])carbonyl)-(R,S)-2-methylpropyl]amide;

xliv. BTD-[1-(2-(5-(3-methylbenzyl)-1,3,4-oxadiazolyl[]])carbonyl)-2-(S)-methylpropyl]amide;

xlv. (R,S)-3-[A]amino-2-oxo-5-phenyl-1,4[,]-benzodiazepine-N-[1-(2-(5-(3-methylbenzy[]])-1,3,4-oxadiazolyl[]])carbonyl)-2-(S)-methylpropyl]acetamide;
xlvi. ([B]benzyloxycarbonyl)-L-valyl-2-L-(2,3-dihydro-1H-indole)-N-[1-(2-(5-(3-methylbenzyl)-1,3,4-oxadiazolyl[]])carbonyl)-2-(S)-methylpropyl]amide;
xlvii. ([B]benzyloxycarbonyl)-L-valyl-2-L-(2,3-dihydro-1H-indole)-N-[1-(3-(5-(3-trifluoromethylbenzyl)-1,2,4-oxadiazolyl[]])carbonyl)-2-(S)-methylpropyl]amide;
xlviii. [A]acetyl-2-L-(2,3-dihydro-1H-indole)-N-[1-(2-(5-(3-methylbenzyl)-1,3,4-oxadiazolyl[]])carbonyl)-2-(S)-methylpropyl]amide;

xlix. 3-(S)-([B]benzyloxycarbonyl)amino)-ε-lactam-N-[1-(2-(5-(3-methylbenzy[]])-1,3,4-oxadiazolyl[]])carbonyl)-2-(S)-methylpropyl]acetamide;

- 1. 3-(S)-([A]amino)-ε-[-]lactam-N-[1-(2-(5-(3-methylbenzyl)-1,3,4-oxadiazolyl[]])carbonyl)-2-(S)-methylpropyl]acetamide trifluoroacetic acid salt;
- li. 3-(S)-[(4-morpholino[]carbonyl-butanoyl)amino]-ε-[-]lactam-N-[1-(2-(5-(3-methylbenzyl)-1,3[,]4-oxadiazolyl[]]]carbonyl)-2-(R,S)-methylpropyl]acetamide;
- lii. 6-[4-[F]fluorophenyl]-ε-lactam-N-[1-(2-(5-(3-methylbenzyl)-1,3,4-oxadiazolyl[]])carbonyl)-2-(S)-methylpropyl]acetamide;
- liii. 2-(2-(R,S)-[P]phenyl-4-oxothiazolidin-3-yl]-N-[1-(2-(5-(3-methylbenzyl)-1,3,4[]-oxadiazolyl[]])carbonyl)-2-(S)-methylpropyl]acetamide;

- liv. 2-(2-(R,S)-phenyl-4-oxothiazolidin-3-yl]-N-[1-(2-(5-(3-methylbenzyl)-1,3,4[]-oxadiazolyl[]])hydroxymethyl)-2-(S)-methylpropyl]acetamide;
- lv. 2-(2-(R,S)-[B]benzyl-4-oxothiazolidin-3-yl]-N-[1-(2-(5-(3-methylbenzyl)-1,3,4[]-oxadiazolyl[]])carbonyl)-2-(S)-methylpropyl][-]acetamide;
- lvi. 2-(2-(R,S)-[B]<u>b</u>enzyl-4-oxothiazolidin-3-yl oxide]-N-[1-(3-(5-(3-trifluoromethylbenzyl)-1,2,4-oxadiazolyl[]])carbonyl)-2-[](R,S,)-methylpropyl]acetamide;
- lvii. (1-[B]benzoyl-3,8-quinazolinedione)-N-[1-(2-(5-(3-methylbenzyl)-1,3,4-oxadiazolyl[]])carbonyl)-2-(S)-methylpropyl]acetamide;
- lviii. (1-[B]<u>b</u>enzoyl-3,6-piperazinedione)-N-[1-(2-(5-(3-methylbenzyl)-1,3,4-oxadiazolyl[]])carbonyl)-2-(S)-methylpropyl]acetamide;
- lix. (1-[P]phenyl-3,6-piperazinedione)-N-[1-(2-(5-(3-methylbenzyl)-1,3,4-oxadiazolyl[]])carbonyl)-2-(S)-methylpropyl]acetamide;
- lx. [[](1-[P]phenyl-3,6-piperazinedione)-N-[1-(3-(5-(3-trifluoromethylbenzyl)-1,2,4[]-oxadiazolyl[]])carbonyl)]-2-(S)-methylpropyl]acetamide;
- lxi. 3-[([B]benzyloxycarbonyl)amino]-quinolin-2-one-N-[1-(2-(5-(3-methylbenzyl)-1,3,4-oxadiazolyl[]])carbonyl)-2-(S)-methylpropyl]acetamide;
- lxii. 3-[([B]benzyloxycarbonyl)amino]-7-piperidinyl-quinolin-2-one-N-[1-(2-(5-(3-methylbenzyl)-1,3,4-oxadiazolyl[]])carbonyl)-2-(S)-methylpropyl]acetamide;
- lxiii. 3-([C]carbomethoxy-quinolin-2-one-N-[1-(2-(5-(3-methybenzyl)-1,3,4-oxadiazoly[]][]])carbonyl)-2-(S)-methylpropyl]acetamide;
- lxiv. 3-([A]amino-quinolin-2-one)-N-[1-(2-(5-(3-methylbenzyl)-1,3,4-oxadiazolyl[]])carbonyl)-2-(S)-methylpropyl]acetamide;

lxv. 3-[(4-[M]morpholino)aceto]amino-quinolin-2-one-N-[1-(2-(5-(3-methylbenzyl)-1,[]3,4-oxadiazolyl[]])carbonyl)-2-(S)-methylpropyl]acetamide; 3,4-[D]dihydro-quinolin-2-one-N-[1-(2-(5-(3-methylbenzyl)-1,3,4oxadiazolyl[]])carbonyl)-2-(S)-methylpropyl]acetamide; lxvii. 1-[A]acetyl-3-(4-fluorobenzylidene)[]piperazine-2,5-dione-N-[1-(2-(5-(3methylbenzyl)-1,3,4-oxadiazolyl[]])carbonyl)-2-(S)-methylpropyl]acetamide; lxviii. 1-[A]acetyl-3-(4-dimethylamino[]benzylidene)piperazine-2,5-dione-N-[1-(2-(5-(3-methylbenzyl)-1,3,4-oxadiazolyl[]])carbonyl)-2-(S)-methylpropyl]acetamide; 1-[A]acetyl-3-(4-carbomethoxy[]benzylidene)piperazine-2,5-dione-N-[1-(2-(5-(3-methylbenzyl)-1,3,4-oxadiazolyl[]])carbonyl)-2-(S)-methylpropyl]acetamide; 1-[A]acetyl-3-[(4-pyridyl)methylene]piperazine-2,5-dione-N-[1-(2-(5-(3-methyl] lxx. |benzyl)-1,3,4-oxadiazolyl[]])carbonyl)-2-(S)-methylpropyl]acetamide; 4-[1-[B]benzyl-3-(R)-benzyl-piperazine-2,5[,]-dione]-N-[1-(2-[5-(3methylbenzyl)-1,3,4-oxadiazolyl[]])carbonyl)-2-(S)-methylpropyl]acetamide; lxxii. 4-[1-[B]benzyl-3-(S)-benzyl[]piperazine-2,5[,]-dione]-N-[1-(2-(5-(3methylbenzyl)-1,3,4-oxadiazolyl[]])carbonyl)-2-(S)-methylpropyl]acetamide;

trifluoromethylbenzyl)-1,2,4-oxadiazolyl[]])carbonyl)-2-(S)-methylpropyl]acetamide; lxxiv. 4-[1-[B]benzyl-3-(S)-benzylpiperazine-2,5[,]-dione]-N-[1-(3-(5-(3-trifluoromethylbenzyl)-1,2,4-oxadiazolyl[]])carbonyl)-2-(S)-methylpropyl]acetamide; lxxv. 4-[1-[B]benzyl-3-(S)-benzyl[]piperazine-2,5[,]-dione]-N-[1-(3-(5-(2-trifluoromethylbenzyl)-1,2,4-oxadiazolyl[]])carbonyl)-2-(S)-methylpropyl]acetamide;

1xxiii. 4-[1-[B]benzyl-3(R)-benzylpiperazine-2,5[,]-dione]-N-[1-(3-(5-(3-

dimethylaminoethyl)-1,2,4-oxadiazolyl[]])carbonyl)-2-(S)-methylpropyl]acetamide;

lxxvi. 4-[1-[M]methyl-3-(R,S)-phenylpiperazine-2,5[,]-dione]-N-[1-(3-(5-(3trifluoromethylbenzyl)-1,2,4-oxadiazolyl[]])carbonyl)-2-(S)-methylpropyl]acetamide; lxxvii. 4-[[][[-M]methyl-3-(R,S)-phenyl[]piperazine-2,5[,]-dione]-N-[1-(2-(5-(3methylbenzyl)-1,3,4-oxadiazolyl[]])carbonyl)-2-(S)-methylpropyl]acetamide; lxxviii. 4-[1-(4-[M]morpholino[]ethyl)3-(R)-benzyl[]piperazine-2,5[,]-dione]-N-[1-(2-(5-(3-methylbenzyl)-1,3,4-oxadiazolyl[]])carbonyl)-2-(S)-methylpropyl]acetamide; lxxix. 5-(R,S)-[P]phenyl-2,4-imidazolidinedione-N-[1-(2-(5-(3-methylbenzyl)-1,3,4oxadiazoly[]])carbonyl)-2-(S)-methylpropyl]acetamide; lxxx. 5-(R)-[B]benzyl-2,4-imidazolidinedione-N-[1-(2-(5-(3-methylbenzyl)-1,3,4oxadiazolyl[]])carbonyl)-2-(S)-methylpropyl]acetamide; lxxxi. 5-(S)-[B]benzyl-2,4-imidazolidinedione-N-[1-(2-(5-(3-methylbenzyl)-1,3,4oxadiazolyl[]])carbonyl)-2-(S)-methylpropyl]acetamide; lxxxii. 5-(S)-[B]benzyl-2,4-imidazolidinedione-N-[1-(3-(5-(3-trifluoromethylbenzyl)-1] 1.2.4-oxadiazolyl[]])carbonyl)-2-(S)-methylpropyl]acetamide; lxxxiii. 5-(R)-[B]benzyl-2,4-imidazolidinedione-N-[1-(3-(5-(3-trifluoromethylbenzyl)-1[ ],2,4-oxadiazolyl[]])carbonyl)-2-(S)-methylpropyl]acetamide; lxxxiv. 1-[B]benzyl-4-(R)-benzyl-2,5-imidazolidinedione-N-[1-(2-(5-(3-methylbenzyl)-1[ ],3,4-oxadiazolyl[]])carbonyl)-2-(S)-methylpropyl]acetamide; lxxxv. 1-[B]benzyl-4-(R)-benzyl-2,5-imidazolidinedione-N-[1-(3-(5-(3-trifluoromethyl[ [benzyl]-1,2,4-oxadiazolyl[]]]carbonyl]-2-(S)-methylpropyl]acetamide[,]; pharmaceutically acceptable salts thereof[,]; and combinations thereof.

L. SHAPIRC

Application No.: 09/518,081

- 9. (Twice Amended) The method of Claim 8, in which the effective amount is at least 0.001 and [less than 8.0]no greater than 7.0 g/kg body weight.
- 12. (Twice Amended) The method of Claim 1, in which the therapeutically effective amount is sufficient to provide at least [8]10 pM and [less than 3]no greater than 2 mM of the inhibitor in the biological fluid of the subject.
- 14. (Twice Amended) The method of Claim 1, in which the therapeutically effective amount is sufficient to provide at least [2].5  $\mu$ M and [less than 220]no greater than 200  $\mu$ M in the biological fluid of the subject.
- 16. (Twice Amended) The method of Claim 1, in which the therapeutically effective amount is administered at least once daily and no more than once hourly.
- 18. (Amended) A method of prophylactically treating an individual at risk for a pathological condition that is precipitated at least in part by excessive apoptosis, comprising:

administering to an individual a therapeutically effective amount of at least one [agent exhibiting mammalian  $\alpha_1$ -antitrypsin or  $\alpha_1$ -antitrypsin-like activity]serine protease inhibitor.

19. (Amended) A method for [inhibiting]reducing apoptosis in an in vitro mammalian cell culture, an *ex vivo* mammalian tissue culture, or mammalian organ comprising:

providing to a cell culture, tissue culture, or organ an amount of a serine protease inhibitor sufficient to inhibit apoptosis in said cell culture, tissue culture, or organ wherein a measured amount of apoptosis is indicative of apoptosis activity.

- 23. (Twice Amended) The method of Claim [21]25, in which the serine protease inhibitor is derivatized by esterification, acetylation, or amidation, and wherein the derivatized serine protease inhibitor retains the inhibitory activity.
- 24. (Twice Amended) The method of Claim [23]25, wherein the at least one cell is a cell of a subject, and wherein the amount is sufficient to bring the concentration of serine protease inhibitor in the subject's blood to at least [2].5  $\mu$ M and [less than 220]no greater than 200  $\mu$ M.
- 25. (Twice Amended) A method of reducing apoptosis, comprising providing a serine protease inhibitor to at least one cell and measuring a decrease in apoptosis, wherein the serine protease inhibitor is an oxidation-resistant or free radical-resistant variant of  $\alpha_1$ -antitrypsin; or:
  - i. (benzyloxycarbonyl)-L-valyl-N-[1-(3-(5-(3-trifluoromethylbenzyl)-1,2,4-oxadiazolyl)carbonyl)-2-(S)-methylpropyl]-L-prolinamide;
  - ii. (benzyloxycarbonyl)-L-valyl-N-[1-(3-(5-(2-phenylethyl)-1,2,4-oxadiazolyl)carbonyl)-2-(S)-methylpropyl]-L-prolinamide;

- iii. (benzyloxycarbonyl)-L-valyl-N-[1-(3-(5-(2-methoxybenzyl)-1,2,4-oxadiazolyl)carbonyl)-2-(S)-methylpropyl]-L-prolinamide;
- iv. (benzyloxycarbonyl)-L-valyl-N-[1-(3-(5-(trifluoromethyl)-1,2,4-oxadiazolyl)carbonyl)-2-(S)-methylpropyl]-L-prolinamide;
- v. (benzyloxycarbonyl)-L-valyl-N-[1-(3-(5-(methyl)-1,2,4-oxadiazolyl)carbonyl)-2-(S)-[M]methylpropyl]-L-[P]prolinamide;
- vi. ([B] $\underline{b}$ enzyloxycarbonyl)-L-[V] $\underline{v}$ alyl-N-[1-(3-(5-(difluoromethyl)-1,2,4-oxadiazolyl)[]carbonyl)-2-(S)-[M] $\underline{m}$ ethylpropyl]-L-[P] $\underline{p}$ rolinamide;
- vii. ([B]<u>b</u>enzyloxycarbonyl)-L-[V]<u>v</u>alyl-N-[1-(3-(5-(benzyl)-1,2,4-oxadiazolyl)carbonyl)-2-(S)-[M]<u>m</u>ethylpropyl]-L-[P]<u>p</u>rolinamide;
- viii. ([B]<u>b</u>enzyloxycarbonyl)-L-[V]<u>v</u>alyl-N-[1-(3-(5-(3-methoxybenzyl)-1,2,4-oxadiazolyl)carbonyl)-2-(S)-[M]<u>m</u>ethylpropyl]-L-[P]<u>p</u>rolinamide;
- ix. ([B] $\underline{b}$ enzyloxycarbonyl)-L-[V] $\underline{v}$ alyl-N-[1-(3-(5-(2,6-difluorobenzyl)-1,2,4-oxadiazolyl)carbonyl)-2-(S)-[M] $\underline{m}$ ethylpropyl]-L-[P] $\underline{p}$ rolinamide;
- x. ([B] $\underline{b}$ enzyloxycarbonyl)-L-[V] $\underline{v}$ alyl-N-[1-(3-(5-(trans-styryl)-1,2,4-oxadiazolyl)carbonyl)-2-(S)-[M] $\underline{m}$ ethylpropyl]-L-[P] $\underline{p}$ rolinamide;
- xi. ([B]<u>b</u>enzyloxycarbonyl)-L-[V]<u>v</u>alyl-N-[1-(3-(5-(trans-4-[T]<u>t</u>rifluoro methylstyryl)-1,2,4-oxadiazolyl)carbonyl)-2-(S)-[M]<u>m</u>ethylpropyl]-L-[P]<u>p</u>rolinamide;
- xii. ([B]<u>b</u>enzyloxycarbonyl)-L-[V]<u>v</u>alyl-N-[1-(3-(5-(trans-4-[M]<u>m</u>ethoxystyryl)-1,2,4-oxadiazolyl)carbonyl)-2-(S)-[M]<u>m</u>ethylpropyl]-L-[P]<u>p</u>rolinamide;
- xiii. ([B]<u>b</u>enzyloxycarbonyl)-L-[V]<u>v</u>alyl-N-[1-(3-(5-(3-[T]<u>t</u>hienylmethyl)-1,2,4-oxadiazolyl)carbonyl)-2-(S)-[M]<u>m</u>ethylpropyl]-L-[P]<u>p</u>rolinamide;

- xiv. ([B] $\underline{b}$ enzyloxycarbonyl)-L-[V] $\underline{v}$ alyl-N-[1-(3-(5-([P] $\underline{p}$ henyl)-1,2,4-oxadiazolyl)carbonyl[])-2-(S)-methylpropyl]-L-prolinamide;
- xv. ([B] $\underline{b}$ enzyloxycarbonyl)-L-[V] $\underline{v}$ alyl-N-[1-(3-(5-(3-[P] $\underline{p}$ henylpropyl)-1,2,4-oxadiazolyl)carbonyl)-2-(S)-[M] $\underline{m}$ ethylpropyl]-L-[P] $\underline{p}$ rolinamide;
- xvi. [B](benzyloxycarbonyl)-L-valyl-N-[1-(2-[[](5-(3-methylbenzyl)-1,3,4-oxadiazolyl[]])carbonyl)-2-(S)-methylpropyl]-L-prolinamide (also known as CE-2072)[,];
- xvii. [B](benzyloxycarbonyl)-L-valyl-N-[1-(2-(3-(methylbenzyl)-1,3,4-oxadiazolyl[]])carbonyl)-2-(S)-methylpropyl]-L-prolinamide;
- xviii. [B](benzyloxycarbonyl)-L-valyl-N-[1-(2-(5-(methyl)-1,3,4-oxadiazoly[]])carbonyl)-[]2-(S)-methylpropyl]-L-prolinamide;
- xix. [B](benzyloxycarbonyl)-L-valyl-N-[1-(2-(5-(3-trifluoromethylbenzyl)-1,3,4-oxadiazolyl[]])carbonyl)-2-(S)-methylpropyl]-L-prolinamide;
- xx. ([B]benzyloxycarbonyl)-L-valyl-N-[1-(2-(5-(4-[D]dimethylamino[]benzyl)-1,3,4-oxadiazolyl[]])carbonyl)-2-(S)-methylpropyl]-L-prolinamide;
- xxi. [B]<u>b</u>enzyloxycarbonyl)-L-valyl-N-[1-(2-(5-(1-napthylenyl)-1,3,4-oxadiazolyl[]])carbonyl)-2-(S)-methylpropyl]-L-prolinamide;
- xxii. ([B]benzyloxycarbonyl)-L-valyl-[1-(3-(5-(3,4-methylenedioxybenzyl)-1,2,4[]-oxadiazolyl[]])carbonyl)-2-(S)-methylpropyl]-L-prolinamide;
- xxiii. [B](benzyloxycarbonyl)-L-valyl-N-[1-(3-(5-(3,5-dimethylbenzyl)-1,2,4-oxadiazolyl[]])carbonyl)-2-(S)-methylpropyl]-L-prolinamide;
- xxiv. ([B]benzyloxycarbonyl)-L-valyl-N-[1-(3-(5-(3,5-dimethoxybenzyl)-1,2,4-oxadiazolyl[]])carbonyl)-2-(S)-methylpropyl]-L-prolinamide;

([B]benzyloxycarbonyl)-L-valyl-N-[1-(3-(5-(3,5-ditrifluoromethylbenzyl)-1,2,4[ XXV. ]-oxadiazolyl[]])carbonyl)-2-(S)-methylpropyl]-L-prolinamide; xxvi. ([B]benzyloxycarbonyl)-L-valyl-N-[1-(3-(5-(3-methylbenzyl)-1,2,4-oxadiazolyl[] ])carbonyl)-2-(S)-methylpropyl]-L-prolinamide; xxvii. ([B]benzyloxycarbonyl)-L-valyl-N-[1-(3-(5-(biphenylmethine)-1,2,4-oxadiazolyl []])carbonyl)-2-(S)-methylpropyl]-L-prolinamide; xxviii. ([B]benzyloxycarbonyl)-L-valyl-N-[1-(3-(5-(4-phenylbenzyl)-1,2,4-oxadiazolyl[] ])carbonyl)-2-(S)-methylpropyl]-L-prolinamide; xxix. ([B]benzyloxycarbonyl)-L-valyl-N-[1-(3-(5-(3-phenylbenzyl)-1,2,4-[ loxadiazolyl[]])carbonyl)-2-(S)-methylpropyl]-L-prolinamide; ([B]benzyloxycarbonyl)-L-valyl-N-[1-(3-(5-(3-phenoxybenzyl)-1,2,4-XXX. oxadiazolyl[]])carbonyl)-2-(S)-methylpropyl]-L-prolinamide; xxxi. ([B]benzyloxycarbonyl)-L-valyl-N-[1-(3-(5-(cyclohexylmethylene)-1,2,4oxadiazolyl[]])carbonyl)-2-(S)-methylpropyl]-L-prolinamide; xxxii. ([B]benzyloxycarbonyl)-L-valyl-N-[1-(3-(5-(3trifluoromethyldimethylmethylene[])-1,2,4-oxadiazolyl[]])carbonyl)-2-(S)methylpropyl]-L-prolinamide; xxxiii. ([B]benzyloxycarbonyl)-L-valyl-N-[1-(3-(5-(1-napthylmethylene)-1,2,4oxadiazoly[]])carbonyl)-2-(S)-methylpropyl]-L-prolinamide; xxxiv. ([B]benzyloxycarbonyl)-L-valyl-N-[1-(3-(5-(3-pyridylmethyl)-1,2,4oxadiazolyl[]])carbonyl)-2-(S)-methylpropyl]-L-prolinamide; xxxv. ([B]benzyloxycarbonyl)-L-valyl-N-[1-(3-(5-(3,5-diphenylbenzyl)-1,2,4-

oxadiazoly[]])carbonyl)-2-(S)-methylpropyl]-L-prolinamide;

xxxvi. ([B]<u>b</u>enzyloxycarbonyl)-L-valyl-N-[1-(3-(5-(4-dimethylaminobenzyl)-1,2,4-oxadiazolyl[]])carbonyl)-2-(S)-methylpropyl]-L-prolinamide;

xxxvii. 2-[(][5-[([B]benzyloxycarbonyl)amino]-6-oxo-2-(4-fluorophenyl)-1,6-dihydro-1-pyrimidinyl]-N-[1-(3-(5-(3-trifluoromethylbenzyl)-1,2,4-oxadiazolyl[]])carbonyl)-[](S)-2-methylpropyl]acetamide;

xxxviii. 2-(5-[A]amino-6-oxo-2-(4-fluorophenyl)-1,6-dihydro-1-pyrimidinyl]-N[1-(3-(5-[](3-trifluoromethylbenzyl)-1,2,4-oxadiazolyl[]])carbonyl)-2-(S)methylpropyl]acetamide;

xxxix. 2-[()][5-[([B]]benzyloxycarbonyl)amino]-6-oxo-2-(4-fluorophenyl)-1,6-dihydro-1-pyrimidinyl]-N-[1-(2-(5-(3-methylbenzyl)-1,3,4-oxadiazolyl[]]]carbonyl)-(S)-2-methylpropyl]acetamide;

- xl. 2-[(][5-[A]amino-6-oxo-2-(4-fluorophenyl)-1,6-dihydro-1-pyrimidinyl]-N-[1-(2-(5-[](3-methylbenzyl)-1,3,4-oxadiazolyl[]])carbonyl)-2-methylpropyl]acetamide;
- xli. ([P]pyrrole-2-carbonyl)-N-(benzyl)glycyl-N-[1-(2-(5-(3-methylbenzyl)-1,3,4-oxadiazolyl[]])carbonyl)-2-(S)-methylpropyl]amide;
- xlii. ([P]pyrrole-2-carbonyl)-N-(benzyl)glycyl-N-[1-(3-(5-(3-trifluoromethylbenzyl)[]](-1,2,4-oxadiazolyl)-(S)-methylpropyl]amide;

xliii. (2S,5S)-5-[A]amino-1,2,4,5,6,7-hexahydroazepino-[3,2,1]-indole-4-one-carbonyl[]-N-[1-(2-(5-(3-methylbenzyl)-1,3,4-oxadiazolyl[]])carbonyl)-(R,S)-2-methylpropyl]amide;

xliv. BTD-[1-(2-(5-(3-methylbenzyl)-1,3,4-oxadiazolyl[]])carbonyl)-2-(S)-methylpropyl]amide;

L. SHAPIRO Application No.: 09/518,081

xlv. (R,S)-3-[A]amino-2-oxo-5-phenyl-1,4[,]-benzodiazepine-N-[1-(2-(5-(3-methylbenzy[]])-1,3,4-oxadiazolyl[]])carbonyl)-2-(S)-methylpropyl]acetamide;
xlvi. ([B]benzyloxycarbonyl)-L-valyl-2-L-(2,3-dihydro-1H-indole)-N-[1-(2-(5-(3-methylbenzyl)-1,3,4-oxadiazolyl[]])carbonyl)-2-(S)-methylpropyl]amide;
xlvii. ([B]benzyloxycarbonyl)-L-valyl-2-L-(2,3-dihydro-1H-indole)-N-[1-(3-(5-(3-trifluoromethylbenzyl)-1,2,4-oxadiazolyl[]])carbonyl)-2-(S)-methylpropyl]amide;
xlviii. [A]acetyl-2-L-(2,3-dihydro-1H-indole)-N-[1-(2-(5-(3-methylbenzyl)-1,3,4-oxadiazolyl[]])carbonyl)-2-(S)-methylpropyl]amide;

- xlix. 3-(S)-([B]benzyloxycarbonyl)amino)-ε-lactam-N-[1-(2-(5-(3-methylbenzy[]])-1,3,4-oxadiazolyl[]])carbonyl)-2-(S)-methylpropyl]acetamide;
- 3-(S)-([A]amino)-ε-[-]lactam-N-[1-(2-(5-(3-methylbenzyl)-1,3,4-oxadiazolyl[]])carbonyl)-2-(S)-methylpropyl]acetamide trifluoroacetic acid salt;
- li. 3-(S)-[(4-morpholino[]carbonyl-butanoyl)amino]-ε-[-]lactam-N-[1-(2-(5-(3-methylbenzyl)-1,3[, ]4-oxadiazolyl[]])carbonyl)-2-(R,S)-methylpropyl]acetamide;
- lii. 6-[4-[F]<u>f</u>luorophenyl]-ε-lactam-N-[1-(2-(5-(3-methylbenzyl)-1,3,4-oxadiazolyl[]])carbonyl)-2-(S)-methylpropyl]acetamide;
- liii. 2-(2-(R,S)-[P]phenyl-4-oxothiazolidin-3-yl]-N-[1-(2-(5-(3-methylbenzyl)-1,3,4[]-oxadiazolyl[]])carbonyl)-2-(S)-methylpropyl]acetamide;
- liv. 2-(2-(R,S)-phenyl-4-oxothiazolidin-3-yl]-N-[1-(2-(5-(3-methylbenzyl)-1,3,4[]-oxadiazolyl[]])hydroxymethyl)-2-(S)-methylpropyl]acetamide;
- lv. 2-(2-(R,S)-[B]benzyl-4-oxothiazolidin-3-yl]-N-[1-(2-(5-(3-methylbenzyl)-1,3,4[]-oxadiazolyl[]])carbonyl)-2-(S)-methylpropyl][-]acetamide;

lvi. 2-(2-(R,S)-[B]benzyl-4-oxothiazolidin-3-yl oxide]-N-[1-(3-(5-(3-trifluoromethylbenzyl)-1,2,4-oxadiazolyl[]])carbonyl)-2-[](R,S,)-methylpropyl]acetamide;

lvii. (1-[B]<u>b</u>enzoyl-3,8-quinazolinedione)-N-[1-(2-(5-(3-methylbenzyl)-1,3,4-oxadiazolyl[]])carbonyl)-2-(S)-methylpropyl]acetamide;

lviii. (1-[B]<u>b</u>enzoyl-3,6-piperazinedione)-N-[1-(2-(5-(3-methylbenzyl)-1,3,4-oxadiazolyl[]])carbonyl)-2-(S)-methylpropyl]acetamide;

lix. (1-[P]phenyl-3,6-piperazinedione)-N-[1-(2-(5-(3-methylbenzyl)-1,3,4-oxadiazolyl[]])carbonyl)-2-(S)-methylpropyl]acetamide;

lx. [[](1-[P]phenyl-3,6-piperazinedione)-N-[1-(3-(5-(3-trifluoromethylbenzyl)-1,2,4[]-oxadiazolyl[]])carbonyl)]-2-(S)-methylpropyl]acetamide;

lxi. 3-[([B]<u>b</u>enzyloxycarbonyl)amino]-quinolin-2-one-N-[1-(2-(5-(3-methylbenzyl)-1,3,4-oxadiazolyl[]])carbonyl)-2-(S)-methylpropyl]acetamide;

lxii. 3-[([B]benzyloxycarbonyl)amino]-7-piperidinyl-quinolin-2-one-N-[1-(2-(5-(3-methylbenzyl)-1,3,4-oxadiazolyl[]])carbonyl)-2-(S)-methylpropyl]acetamide;

lxiii. 3-([C]carbomethoxy-quinolin-2-one-N-[1-(2-(5-(3-methybenzyl)-1,3,4-oxadiazoly[]l[]])carbonyl)-2-(S)-methylpropyl]acetamide;

lxiv. 3-([A]amino-quinolin-2-one)-N-[1-(2-(5-(3-methylbenzyl)-1,3,4-oxadiazolyl[]])carbonyl)-2-(S)-methylpropyl]acetamide;

lxv. 3-[(4-[M]morpholino)aceto]amino-quinolin-2-one-N-[1-(2-(5-(3-methylbenzyl)-1,[]3,4-oxadiazolyl[]])carbonyl)-2-(S)-methylpropyl]acetamide;

lxvi. 3,4-[D]dihydro-quinolin-2-one-N-[1-(2-(5-(3-methylbenzyl)-1,3,4-oxadiazolyl[]])carbonyl)-2-(S)-methylpropyl]acetamide;

lxvii. 1-[A]acetyl-3-(4-fluorobenzylidene)[]piperazine-2,5-dione-N-[1-(2-(5-(3methylbenzyl)-1,3,4-oxadiazolyl[]])carbonyl)-2-(S)-methylpropyl]acetamide; lxviii. 1-[A]acetyl-3-(4-dimethylamino[]benzylidene)piperazine-2,5-dione-N-[1-(2-(5-(3-methylbenzyl)-1,3,4-oxadiazolyl[]])carbonyl)-2-(S)-methylpropyl]acetamide; 1-[A]acetyl-3-(4-carbomethoxy[]benzylidene)piperazine-2,5-dione-N-[1-(2-(5-(3-methylbenzyl)-1,3,4-oxadiazolyl[]])carbonyl)-2-(S)-methylpropyl]acetamide; 1-[A]acetyl-3-[(4-pyridyl)methylene]piperazine-2,5-dione-N-[1-(2-(5-(3-methyl[ lxx. |benzyl)-1,3,4-oxadiazolyl[]])carbonyl)-2-(S)-methylpropyl]acetamide; 4-[1-[B]benzyl-3-(R)-benzyl-piperazine-2,5[,]-dione]-N-[1-(2-[5-(3methylbenzyl)-1,3,4-oxadiazolyl[]])carbonyl)-2-(S)-methylpropyl]acetamide; lxxii. 4-[1-[B]benzyl-3-(S)-benzyl[]piperazine-2,5[,]-dione]-N-[1-(2-(5-(3methylbenzyl)-1,3,4-oxadiazolyl[]])carbonyl)-2-(S)-methylpropyl]acetamide; lxxiii. 4-[1-[B]benzyl-3(R)-benzylpiperazine-2,5[,]-dione]-N-[1-(3-(5-(3trifluoromethylbenzyl)-1,2,4-oxadiazolyl[]])carbonyl)-2-(S)-methylpropyl]acetamide; lxxiv. 4-[1-[B]benzyl-3-(S)-benzylpiperazine-2,5[,]-dione]-N-[1-(3-(5-(3trifluoromethylbenzyl)-1,2,4-oxadiazolyl[]])carbonyl)-2-(S)-methylpropyl]acetamide; lxxv. 4-[1-[B]benzyl-3-(S)-benzyl[]piperazine-2,5[,]-dione]-N-[1-(3-(5-(2dimethylaminoethyl)-1,2,4-oxadiazolyl[]])carbonyl)-2-(S)-methylpropyl]acetamide; lxxvi. 4-[1-[M]methyl-3-(R,S)-phenylpiperazine-2,5[,]-dione]-N-[1-(3-(5-(3trifluoromethylbenzyl)-1,2,4-oxadiazolyl[]])carbonyl)-2-(S)-methylpropyl]acetamide; 1xxvii. 4-[[][[-M]methyl-3-(R,S)-phenyl[]piperazine-2,5[,]-dione]-N-[1-(2-(5-(3methylbenzyl)-1,3,4-oxadiazolyl[]])carbonyl)-2-(S)-methylpropyl]acetamide;

lxxviii. 4-[1-(4-[M]morpholino[]ethyl)3-(R)-benzyl[]piperazine-2,5[,]-dione]-N-[1-(2-(5-(3-methylbenzyl)-1,3,4-oxadiazolyl[]])carbonyl)-2-(S)-methylpropyl]acetamide; lxxix. 5-(R,S)-[P]phenyl-2,4-imidazolidinedione-N-[1-(2-(5-(3-methylbenzyl)-1,3,4-oxadiazolyl[]])carbonyl)-2-(S)-methylpropyl]acetamide;

lxxx. 5-(R)-[B]benzyl-2,4-imidazolidinedione-N-[1-(2-(5-(3-methylbenzyl)-1,3,4-oxadiazolyl[]])carbonyl)-2-(S)-methylpropyl]acetamide;

lxxxi. 5-(S)-[B]<u>b</u>enzyl-2,4-imidazolidinedione-N-[1-(2-(5-(3-methylbenzyl)-1,3,4-oxadiazolyl[]])carbonyl)-2-(S)-methylpropyl]acetamide;

lxxxii. 5-(S)-[B]<u>b</u>enzyl-2,4-imidazolidinedione-N-[1-(3-(5-(3-trifluoromethylbenzyl)-1[],2,4-oxadiazolyl[]])carbonyl)-2-(S)-methylpropyl]acetamide;

lxxxiii. 5-(R)-[B]<u>b</u>enzyl-2,4-imidazolidinedione-N-[1-(3-(5-(3-trifluoromethylbenzyl)-1[],2,4-oxadiazolyl[]])carbonyl)-2-(S)-methylpropyl]acetamide;

lxxxiv. 1-[B]benzyl-4-(R)-benzyl-2,5-imidazolidinedione-N-[1-(2-(5-(3-methylbenzyl)-1[],3,4-oxadiazolyl[]])carbonyl)-2-(S)-methylpropyl]acetamide;

lxxxv. 1-[B]<u>b</u>enzyl-4-(R)-benzyl-2,5-imidazolidinedione-N-[1-(3-(5-(3-trifluoromethyl[]benzyl)-1,2,4-oxadiazolyl[]])carbonyl)-2-(S)-methylpropyl]acetamide[,];
pharmaceutically acceptable salts thereof[,];

and combinations thereof.